1. Home
  2. Clinical Topics
  3. FDA announces guidelines for polymyxin, vecuronium recall
Clinical TopicsDrugs and DevicesHealthcare & TechnologyWeb Exclusives

FDA announces guidelines for polymyxin, vecuronium recall

On Jan. 12, The U.S. Food and Drug Administration announced that Bedford Laboratories states certain vials of polymyxin and vecuronium bromide, recalled because of the possibility of glass particles, should not be used but should be returned to the manufacturer. Access the affected lot numbers here.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.


Recent Posts